LONDON, September 20, 2017 /PRNewswire/ --
Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs
The world cancer-treating drugs market is expected to grow at a CAGR of 6.6% in the second half of the forecast period. The market reached $102bn in 2016, dominated by the immunotherapy segment which held 44.1% share of the market.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 194-page report you will receive 110 tables and 101 figures - all unavailable elsewhere.
The 194-page report provides clear detailed insight into the world cancer-treating drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• World cancer-treating drugs market forecasts from 2017-2027
• This report also breaks down the revenue forecast for the world cancer-treating drugs market by its leading segments:
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Hormone Therapy
Each sector is analysed and revenue forecasts presented.
• This report discusses and forecasts revenues of the top 25 anti-cancer drugs:
- Avastin
- Herceptin
- Rituxan
- Gleevec
- Revlimid
- Alimta
- Velcade
- Erbitux
- Gardasil
- Zytiga
- Xeloda
- Tarceva
- Afinitor
- Sprycel
- Tasigna
- Sutent
- Nexavar
- Xgeva
- Zoladex
- Yervoy
- Vidaza
- Treanda
- Temodar
- Faslodex
- Abraxane
- Others
• This report provides individual revenue forecasts to 2027 for these regional and national markets:
- North America: US, Canada, Mexico
- South America: Brazil, Argentina, Paraguay, Brazil, Rest of South America
- Europe: The UK, Germany, France, Spain, Italy, Rest of Europe
- Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific
- Rest of World: Middle East, Africa, Other Countries
• This report discusses trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the cancer-treating drugs market
• Our study discusses the selected leading companies that are the major players in the cancer-treating drugs market:
- AstraZeneca
- Merck & Co., Inc. (Merck)
- Novartis
- Amgen
- Bristol-Myers Squibb (BMS)
- GlaxoSmithKline (GSK)
- Johnson & Johnson (J&J)
- Roche
- Eli Lilly
- Celgene
The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.
Visiongain's study is intended for anyone requiring commercial analyses for the world cancer-treating drugs market. You find data, trends and predictions.
Buy our report today World Cancer-Treating Drugs Market Forecast 2017-2027: Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs.
To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/1995/World-Cancer-Treating-Drugs-Market-Forecast-2017-2027
List of Companies Mentioned in the Report
AbbVie
Active Biotech
Advaxis
Alchemia
Allergan
Amgen
AmpImmune
Argos Therapeutics
ArQule
AstraZeneca
Barvarian Nordic
Bayer
Biothera
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Celator Pharmaceuticals
Celgene
Cephalon
Clovis Oncology
Cyclacel
Daiichi Sankyo
Dendreon
Dr. Reddy's Laboratories
Eisai
Eli Lilly
EMA
Sanofi
EMD Serono
Galena Biopharma
Gilead
GSK
Heat Biologics
Immatics Biotechnologies
Infinity Pharmaceuticals
Inovio Pharmaceuticals
Janssen
Jennerex Biotherapeutics
Jiangsu Hengrui Medicine
Johnson & Johnson
MedImmune
Merck & Co.
Merck KGaA
Merck Sharpe and Dohme
Merrimack
Newlink
Novartis
OncoGenex
Onyx
Orion
OSi Pharmaceuticals
Petrov Institute of Oncology
Pfizer
Pharmacyclics
Progen Pharmaceuticals
Puma Biotechnology
Roche
Spectrum Pharmaceuticals
Spirogen
Sun Pharma
Sunesis Pharmaceuticals
Syndax
Takeda
Telomedix
TESARO
Teva Pharmaceuticals
Tracon Pharma
Transgene
United Therapeutics
Vaccinogen
Viventia Biotech
Xbiotech
To see a report overview please email Sara Peerun on sara.peerun@visiongain.com
Share this article